Clinical trial
Extension Study of a Study to Evaluate Efficacy and Safety of Imatinib (Glinib®) 600mg/Day Depending on Early Molecular Response in Newly Diagnosed Patients With Chronic Myeloid Leukemia in Chronic Phase
NCT02421926 is registered in ClinicalTrials.gov with Asan Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Extension Study of a Study to Evaluate Efficacy and Safety of Imatinib (Glinib®) 600mg/Day Depending on Early Molecular Response in Newly Diagnosed Patients With Chronic Myeloid Leukemia in Chronic Phase
- Lead sponsor
- Asan Medical Center
- Phase
- Observational
- Overall status
- Withdrawn
- Start date
- October 31, 2014
- Completion date
- May 31, 2023
- Enrollment
- 0 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.